SynthesisFrontiers in endocrinology2026
Predictive factors of permanent hypothyroidism after subacute thyroiditis: a systematic review and meta-analysis.
Synthesis in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Subacute thyroiditis (SAT) is a self-limiting thyroid inflammatory disorder, but some patients develop permanent hypothyroidism, impacting long-term health. We aimed to systematically synthesize evidence on factors associated with permanent hypothyroidism after SAT. Methods: A systematic search of PubMed, Embase, the Cochrane Library and Web of Science was conducted up to August 2025. Randomized trials, cohort, and case-control studies evaluating predictors of permanent hypothyroidism after SAT were included. Data were extracted following PRISMA guidelines, and study quality was assessed using the Newcastle-Ottawa Scale (NOS). Random-effects models were preferentially applied given expected clinical heterogeneity, with heterogeneity quantified using I Results: Ten studies involving 1294 patients were included. Higher free triiodothyronine (FT3) levels (mean difference = 1.85, 95% CI: 0.60-3.09; Z = 2.91, P = 0.004; I² = 0%) and positive thyroglobulin antibodies (TgAb) (OR = 2.57, 95% CI: 1.35-4.88, P = 0.004; I² = 57%, τ² = 0.13) were significantly associated with an increased risk of permanent hypothyroidism after SAT. Corticosteroid therapy was associated with a lower odds of permanent hypothyroidism compared with NSAID-based management (OR = 0.40, 95% CI: 0.23-0.70, P = 0.001; I² = 36%). Conclusions: FT3, TgAb positivity and treatment modality are associated with the risk of permanent hypothyroidism following SAT. Compared with NSAID-based management, corticosteroid therapy is associated with lower odds of developing permanent hypothyroidism. These findings support early identification of high-risk patients and personalized follow-up strategies. Systematic review registration: https://www.crd.york.ac.uk/prospero/, identifier CRD420251064643.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.